This annual publication provides the only comprehensive listing of all AIDS vaccine clinical trial activity worldwide.
Last year saw the start of the first AIDS vaccine trials in the Russian Federation and Zambia, and three countries in sub-Saharan Africa —Kenya, Uganda, and Tanzania—also initiated new trials. The United States, United Kingdom, Sweden and Peru began new trials in 2006 as well. Many of these trials were sponsored by new research groups, including the Karolinska Institute in Sweden, St. George’s University of London and the Moscow Institute of Immunology.
All of the new trials that began last year were either Phase I or Phase I/II trials designed to evaluate the safety and immunogenicity of the candidate vaccines. “Although these new trials are early-stage, they will provide critical information over the coming years that will help drive the field’s R&D agenda. We hope to begin to see even more novel vectors, as well as approaches that target neutralizing antibodies in the next few years,” said CEO and President of IAVI, Dr. Seth Berkley.
IAVI and its collaborators are currently conducting four ongoing trials in India, Kenya, Rwanda, Uganda, South Africa and the United States. In 2006, IAVI launched a Phase II trial in Uganda and Zambia, part of a multi-site study that also included three sites in South Africa. The South Africa, Uganda and Zambia trial sites are now fully enrolled with data expected later this year.
Two of the most advanced trials underway in 2007 are from Sanofi-Pasteur and Merck & Co., Inc. Data from Merck’s ongoing Phase IIb test-of-concept trial with its adeno-5 vector vaccine candidate is expected in 2008-2009 and will provide preliminary information on the efficacy of this type of vaccine candidate. These results will have significant implications for the field’s future research and development efforts. The company will also soon be starting an additional Phase IIb trial with the same candidate in South Africa.
The Joint United Nations Programme on HIV/AIDS (UNAIDS) estimates that 4.3 million people were newly infected with HIV last year—bringing the total number of HIV-infected individuals to 40 million people worldwide. Explosive HIV epidemics also continue in Eastern Europe and Central Asia. Throughout the world, a preventive AIDS vaccine remains one of the greatest hopes for stemming the pandemic.
The 2006 IAVI VAX Map, which provides detailed information on all ongoing preventive AIDS vaccine trials, is available at http://www.iavireport.org/Vax/VAXJanuary2007.asp.
Hester Kuipers | alfa
Researchers release the brakes on the immune system
18.10.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn
Norovirus evades immune system by hiding out in rare gut cells
12.10.2017 | University of Pennsylvania School of Medicine
University of Maryland researchers contribute to historic detection of gravitational waves and light created by event
On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...
Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.
Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....
Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).
When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...
Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.
How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...
Scientists from the Max Planck Institute of Quantum Optics, using high precision laser spectroscopy of atomic hydrogen, confirm the surprisingly small value of the proton radius determined from muonic hydrogen.
It was one of the breakthroughs of the year 2010: Laser spectroscopy of muonic hydrogen resulted in a value for the proton charge radius that was significantly...
17.10.2017 | Event News
10.10.2017 | Event News
10.10.2017 | Event News
20.10.2017 | Interdisciplinary Research
20.10.2017 | Materials Sciences
20.10.2017 | Earth Sciences